What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Surgery
Yi-Long Wu mostly deals with Lung cancer, Internal medicine, Oncology, Surgery and Chemotherapy.
His Lung cancer research focuses on Gefitinib in particular.
Internal medicine is a component of his Carboplatin, Hazard ratio, Pemetrexed, Carcinoma and Erlotinib studies.
His biological study spans a wide range of topics, including Phases of clinical research and Adenocarcinoma.
The concepts of his Surgery study are interwoven with issues in Gastroenterology, Placebo, Clinical trial and Icotinib.
Yi-Long Wu has researched Epidermal growth factor receptor in several fields, including Tyrosine kinase and Cancer research.
His most cited work include:
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma (6022 citations)
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study (2762 citations)
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer (2444 citations)
What are the main themes of his work throughout his whole career to date?
Internal medicine, Lung cancer, Oncology, Cancer research and Chemotherapy are his primary areas of study.
Internal medicine is often connected to Surgery in his work.
His Lung cancer study integrates concerns from other disciplines, such as Cancer, Epidermal growth factor receptor and Adenocarcinoma.
His research in Epidermal growth factor receptor intersects with topics in Tyrosine kinase and Tyrosine-kinase inhibitor.
His Oncology research incorporates elements of Carboplatin, Clinical endpoint, Clinical trial and Carcinoma.
Yi-Long Wu combines subjects such as Mutation, KRAS, Anaplastic lymphoma kinase, Crizotinib and Immunotherapy with his study of Cancer research.
He most often published in these fields:
- Internal medicine (60.82%)
- Lung cancer (57.52%)
- Oncology (52.16%)
What were the highlights of his more recent work (between 2019-2021)?
- Internal medicine (60.82%)
- Oncology (52.16%)
- Lung cancer (57.52%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Internal medicine, Oncology, Lung cancer, Cancer research and Chemotherapy.
His study in Gefitinib, Hazard ratio, Clinical endpoint, Lung and Tolerability falls within the category of Internal medicine.
His Oncology study combines topics in areas such as Adjuvant therapy and Clinical trial, Phases of clinical research.
His Lung cancer research is multidisciplinary, incorporating elements of Cancer, Epidermal growth factor receptor, Adverse effect and Exon.
Yi-Long Wu interconnects Tyrosine kinase, T cell, Anaplastic lymphoma kinase, Carcinoma and Crizotinib in the investigation of issues within Cancer research.
His studies in Chemotherapy integrate themes in fields like Retrospective cohort study and Overall survival.
Between 2019 and 2021, his most popular works were:
- COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. (181 citations)
- Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA. (33 citations)
- Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR / ALK wild-type advanced non-small cell lung cancer. (25 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
His scientific interests lie mostly in Internal medicine, Oncology, Lung cancer, Cancer research and Chemotherapy.
His studies deal with areas such as Lung, Cohort and Immunotherapy as well as Oncology.
His study in Lung cancer focuses on Non small cell in particular.
His research on Cancer research also deals with topics like
- Anaplastic lymphoma kinase, which have a strong connection to Crizotinib, Carcinoma and Tyrosine-kinase inhibitor,
- Missense mutation, which have a strong connection to Nivolumab, Ipilimumab and Tyrosine.
In his study, which falls under the umbrella issue of Chemotherapy, Carboplatin, Mutational status and First line therapy is strongly linked to Pembrolizumab.
His study in Hazard ratio is interdisciplinary in nature, drawing from both Gastroenterology, Clinical endpoint and Response Evaluation Criteria in Solid Tumors.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
